Recommendation mean of Retrophin, Inc.
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|BTX BioTime, Inc.||NYSEMKT > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||3.86|
|RADA RADA Electronic Industries Ltd.||NASDAQ > Consumer Non-Durables > Electronic Components||3.87|
|CRUS Cirrus Logic, Inc.||NASDAQ > Technology > Semiconductors||3.87|
|TXN Texas Instruments Incorporated||NASDAQ > Technology > Semiconductors||3.87|
|ARWR Arrowhead Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.87|
|LPTH LightPath Technologies, Inc.||NASDAQ > Technology > Semiconductors||3.88|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.88|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||297.63|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||762.43|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||812.31|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||966.10|
|HUNT Hunter Maritime Acquisition Corp.||NASDAQ > Transportation > Oil Refining/Marketing||1,687.50|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|